SCHEDULE: Altai Capital Launches Proxy Fight at OraSure Technologies

Altai Capital Management, a 5% shareholder, has launched a proxy contest to elect two new directors to OraSure Technologies' board, citing chronic underperformance and misaligned management incentives.

Summary

• Altai Capital Management, holding approximately 5.2% of OraSure Technologies' common stock, is seeking to elect two nominees, Rishi Bajaj and John Bertrand, to the company's Board of Directors at the 2026 Annual Meeting.
• The activist investor argues that OraSure has experienced chronic underperformance, with its share price down 67% over five years and 56% over ten years, significantly lagging peers and broader indices.
• Altai criticizes the current Board for lacking "skin in the game," noting that independent directors collectively own less than 1% of shares while receiving over $250,000 each in annual compensation.
• CEO Carrie Eglinton Manner's compensation, estimated at over $15 million during her tenure, is largely (90%) untied to share price performance, despite shareholders losing 60% of their investment since 2023.
• Altai highlights questionable strategic investments, including a $30 million investment in Sapphiros in January 2024, which failed to accelerate revenue growth, and the acquisition of Sherlock Biosciences for $5 million upfront plus $20 million R&D commitment in December 2024, raising conflict of interest concerns regarding former Board Chair Mara Aspinall.
• OraSure's cash balance declined from $290 million ($3.94 per share) at the end of 2023 to $199 million ($2.88 per share) by year-end 2025, with non-COVID revenue falling 27% from its 2024 run rate to an annualized $107 million.
• The company is operating at approximately 30% manufacturing capacity and does not expect to reach operating cash flow breakeven until 2027, relying on anticipated product launches like Sherlock, which is currently under FDA review.
• Altai proposes a strategic review, including evaluating an outright sale of the business, estimating a potential value of $4.54 to $6.60 per share in a sale, representing a 42% to 107% premium to the current price.
• The nominees, Rishi Bajaj and John Bertrand, bring experience in corporate transformation and healthcare AI diagnostics, with Bajaj having led ContextLogic to a 120%+ share price increase after an acquisition.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative for OraSure's current management and strategy, given the severe criticisms regarding underperformance, cash burn, misaligned incentives, and questionable acquisitions. The sentiment reflects Altai Capital's strong call for immediate and significant change.

Positives

• OraSure's share price increased 18% since Altai Capital announced its formal director nominations in January 2026, suggesting investor encouragement for potential governance changes.
• Altai Capital's nominees, Rishi Bajaj and John Bertrand, have track records of driving shareholder value and relevant industry expertise, with Bajaj having led ContextLogic's transformation resulting in a 120%+ share price increase and Bertrand co-founding Digital Diagnostics, a company behind an FDA-cleared autonomous AI diagnostic solution.

Negatives

• OraSure's share price has dramatically underperformed comparable companies and broader indices, down 67% over five years and 56% over ten years.
• The company has experienced repeated operational and strategic failures under current management, leading to significant shareholder value destruction.
• Independent directors collectively own less than 1% of shares outstanding, indicating a lack of "skin in the game," despite receiving over $250,000 each per year in compensation.
• CEO Carrie Eglinton Manner's compensation structure is misaligned with shareholder interests, with over 90% not tied to share price performance, while shareholders have lost 60% of their investment since 2023.
• OraSure invested $30 million in Sapphiros, a startup with no commercial products, in January 2024, with expected revenue growth in 2025 that "never came," and no recent update on the investment status.
• The acquisition of Sherlock Biosciences for $5 million upfront plus a commitment of at least $20 million in R&D costs is questioned due to its merits and potential conflict of interest involving former Board Chair Mara Aspinall.
• Cash balance declined by over $90 million from $290 million at the end of 2023 to $199 million by year-end 2025.
• Non-COVID revenue fell to an annualized rate of $107 million by year-end 2025, a 27% decline from its 2024 run rate.
• The company is operating at approximately 30% manufacturing capacity and does not expect to reach operating cash flow breakeven until 2027, implying continued cash burn.

Risks

• Continued chronic underperformance of the share price if current management and strategy persist.
• Further cash burn due to operating losses (approximately $15 million per quarter) and investments in speculative, early-stage ventures.
• Execution risk associated with new product launches, such as Sherlock Biosciences, which has not yet received FDA approval and generates zero revenue.
• Risk of continued misallocation of capital through value-destructive investments and acquisitions that do not utilize existing manufacturing capacity.
• Potential for ongoing misalignment of management and board incentives with shareholder interests.
• Intense competition and constant pricing pressure in the diagnostics sector, making it difficult for smaller companies like OraSure to achieve profitability without scale.

Future Outlook

Altai Capital believes that if the current strategy persists, OraSure will continue to burn cash and shareholders will endure at least another year of losses while hoping for success from unapproved products. They advocate for a strategic review to either grow revenue through disciplined capital allocation or pursue a sale of the entire business to deliver immediate value to shareholders. The company's CFO does not expect operating cash flow breakeven until 2027, contingent on anticipated product launches.

Management Comments

• Altai Capital Management: "Our case for change at OraSure rests on five pillars: Chronic Underperformance, A Board Without Skin in the Game, Pay Without Performance, The Imperative for a Strategic Review, and Nominees With a Track Record of Results."
• Altai Capital Management: "OraSure must evaluate a sale of the entire business alongside its current plan. We will represent and advocate for all shareholder interests in this process upon our appointment to the Board to ensure that the outcome delivers the best possible returns to shareholders."
• Altai Capital Management: "A company running at 30% capacity should acquire established businesses that can immediately absorb excess manufacturing capacity and improve profitability. Instead, OraSure pursued speculative, early-stage ventures with no near-term production volumes."
• Altai Capital Management: "We believe it is imperative for the Company to reduce its cash burn and safeguard itself against further misuses of cash, including additional value-destructive investments and acquisitions."
• CFO Ken McGrath (OraSure): "OraSure is operating at approximately 30% manufacturing capacity."
• CFO Ken McGrath (OraSure): "The Company does not expect to reach operating cash flow breakeven until 2027, driven by our expected return to revenue growth, including contributions from our anticipated product launches."

Industry Context

StockSavvy.ai notes that the diagnostics sector is characterized by intense competition, constant pricing pressure, and often unstable funding sources, where scale is a critical factor for efficient operation. OraSure's situation, with 30% manufacturing capacity utilization and investments in early-stage ventures, contrasts with the industry need for scale and established revenue streams. Several smaller diagnostics companies are valued at little to nothing by the market, sometimes below their cash value, underscoring the challenges OraSure faces in achieving profitability without significant strategic change.

Comparison to Industry Standards

• OraSure's stock price performance (down 67% over 5 years, 56% over 10 years) dramatically underperformed the Bloomberg US 3000 Life Science & Diagnostics Price Return Index, S&P Health Care Index, NASDAQ Composite Index, and NYSE Composite Index.
• Altai Capital's nominee, Rishi Bajaj, demonstrated a track record of success at ContextLogic, where he led a transformation that resulted in a share price increase of over 120% following a $907.5 million acquisition, a stark contrast to OraSure's recent performance.
• John Bertrand, another Altai nominee, co-founded Digital Diagnostics, a company behind the first FDA-cleared autonomous AI diagnostic solution in healthcare, showcasing expertise in a high-growth, innovative segment of the diagnostics industry, which OraSure's current speculative investments have yet to replicate.
• The compensation structure for OraSure's CEO, with only 10% tied to share price performance, deviates significantly from best practices for companies in distress or undergoing strategic shifts, where a higher proportion of pay is typically at risk and aligned with shareholder returns, as exemplified by Rishi Bajaj's compensation at ContextLogic.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of Sherlock Biosciences by OraSure raised concerns due to Mara Aspinall's dual role: she was Chair of OraSure's Board and a Partner at Illumina Ventures, which had previously invested in Sherlock Biosciences. The company has not detailed her involvement or confirmed her recusal from deliberations and vote related to the transaction.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Altai's strategic review and governance changes are implemented, or continued value destruction if the current strategy persists. The proxy fight itself creates uncertainty but also the possibility of a premium if the company is sold.
• Management: Current management faces scrutiny over performance and compensation. A change in board composition could lead to changes in leadership or compensation structures.
• Board of Directors: Existing independent directors are criticized for lack of ownership and oversight, facing potential replacement and increased accountability.
• Employees: Potential impact from strategic changes, including a possible sale of the business or restructuring to reduce cash burn and improve efficiency.
• Customers/Suppliers: Potential impact from changes in product strategy, acquisitions, or divestitures, depending on the outcome of a strategic review.

Next Steps

• Altai Capital Management intends to solicit proxies from stockholders to elect Rishi Bajaj and John Bertrand at the 2026 Annual Meeting.
• If elected, Rishi Bajaj and John Bertrand will evaluate Sherlock's prospects with open minds.
• If elected, Rishi Bajaj and John Bertrand will seek to initiate a full strategic review, weighing an outright sale against the current plan.
• If elected, Rishi Bajaj and John Bertrand will ensure executive compensation at OraSure is restructured to align with shareholder returns.
• OraSure's management expects to reach operating cash flow breakeven by 2027, contingent on anticipated product launches.
• Sherlock Biosciences' applications are currently under FDA review with potential for approval in the first half of 2026.

Key Dates

Recommendation

Based on Altai Capital's detailed analysis in the filing, OraSure Technologies is suffering from chronic underperformance, significant cash burn, misaligned executive incentives, and questionable strategic investments under its current management and board. The company's core business is declining, and it operates at low capacity with no clear path to profitability until 2027. While Altai's proposed changes offer a potential upside, the current state of the company, as presented, suggests a 'sell' recommendation for investors holding the stock under the existing leadership, given the substantial risks and value destruction highlighted.

Keywords

OraSure Technologies, OSUR, Altai Capital Management, Proxy Contest, Shareholder Activism, Corporate Governance, Strategic Review, Diagnostics, Underperformance, Executive Compensation, Board of Directors, FDA Approval, Cash Burn